EUVIMEDEUVIMED entdecken
Crossref

Single dose tocilizumab for COVID‐19 associated cytokine storm syndrome: Less is more

Niels W Boone iD, Dirk Jan A R Moes, Sofia Ramiro, Remy L M Mostard, Cesar Magro-Checa, Christel M P van Dongen, Michiel Gronenschild, Eric van Haren, Jacqueline Buijs, Annick de Vries, Ralph Peeters, Robert B M Landewé und 1 weitere

British Journal of Clinical Pharmacology · 2025-04 · 91 (4) · 938-946

DOI: 10.1111/bcp.15690 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 24.02.2023. Verfasst von Niels W Boone und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, Pharmacology and Toxicology, Zuyderland Medical Centre, Heerlen, The Netherlands. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Cytokine Release Syndrome, COVID-19 Drug Treatment. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

We aim to evaluate the clinical pharmacokinetics of a single dose interleukin‐6 (IL‐6) antibody tocilizumab (TCZ) in methylprednisolone (MP)‐treated COVID‐19 patients with cytokine storm syndrome (CSS).

Methods

MP pre‐treated patients with COVID‐19‐associated CSS, defined as at least two elevations of C‐reactive protein (CRP) >100 mg/L, ferritin >900 μg/L or D‐dimers >1500 μg/L, received intravenous TCZ (8 mg/kg, max. 800 mg) upon clinical deterioration. A nonlinear‐mixed effects model was developed based on TCZ serum concentrations and dosing information. Population pharmacokinetic parameters were estimated and concentration–time profiles were plotted against individual predicted values. Fixed dose simulations were subsequently performed based on the final model.

Results

In total 40 patients (mean [SD] age: 62 [12] years, 20% female, body weight: 87 [17] kg) with COVID‐19 induced CSS were evaluated on pharmacokinetics and laboratory parameters. A biphasic elimination of TCZ serum concentration was described by a homogeneous population pharmacokinetic model. Serum TCZ concentrations above the 1 μg/L target saturation threshold were covered for 16 days in all evaluated patients treated with a single dose of 8 mg/kg. In a simulation with TCZ 400 mg fixed dose, this condition of full IL‐6 receptor occupancy at minimum serum concentration was also met.

Conclusions

A single dose (8 mg/kg, max. 800 mg) is sufficient to cover a period of 16 days of IL‐6‐mediated hyperinflammation in COVID‐19‐induced CSS in MP‐treated patients. Based on body weight PK simulations, a fixed‐dose tocilizumab of 400 mg should be considered to prevent overtreatment, future drug shortage and unnecessary drug expenditure.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedCytokine Release SyndromeCOVID-19 Drug TreatmentHumansFemaleMiddle AgedMaleCOVID-19AgedMethylprednisoloneModels, BiologicalSARS-CoV-2Interleukin-6 Inhibitors

Stichwörter der Autor:innen

COVID‐19cytokine storm syndromedose rationalepharmacokineticstocilizumab

Substanzen

Antibodies, Monoclonal, HumanizedMethylprednisoloneInterleukin-6 Inhibitorstocilizumab

Autor:innen und Institutionen

  • Department of Clinical Pharmacy, Pharmacology and Toxicology, Zuyderland Medical Centre, Heerlen, The Netherlands.
  • Department of Clinical Pharmacy and Toxicology, Leiden University Medical Centre, Leiden, The Netherlands.
  • Department of Rheumatology, Zuyderland Medical Centre, Heerlen, The Netherlands.
  • Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands.
  • Department of Pulmonology, Zuyderland Medical Centre, Heerlen, The Netherlands.
  • Department of Respiratory Medicine, Maastricht University Medical Centre, Maastricht, The Netherlands.

ORCID-Profile: Niels W Boone

Zitieren

APA

Boone, N. W., Moes, D. J. A. R., Ramiro, S., Mostard, R. L. M., Magro-Checa, C., van Dongen, C. M. P., Gronenschild, M., van Haren, E., Buijs, J., de Vries, A., Peeters, R., Landewé, R. B. M., & Wong, D. R. (2025). Single dose tocilizumab for COVID‐19 associated cytokine storm syndrome: Less is more. British Journal of Clinical Pharmacology, 91(4), 938-946. https://doi.org/10.1111/bcp.15690

Vancouver

Boone NW, Moes DJAR, Ramiro S, Mostard RLM, Magro-Checa C, van Dongen CMP, et al. Single dose tocilizumab for COVID‐19 associated cytokine storm syndrome: Less is more. British Journal of Clinical Pharmacology. 2025;91(4):938-946. doi:10.1111/bcp.15690

BibTeX
@article{Boone2025,
  author = {Boone, Niels W and Moes, Dirk Jan A R and Ramiro, Sofia and Mostard, Remy L M and Magro-Checa, Cesar and van Dongen, Christel M P and Gronenschild, Michiel and van Haren, Eric and Buijs, Jacqueline and de Vries, Annick and Peeters, Ralph and Landewé, Robert B M and Wong, Dennis R},
  title = {Single dose tocilizumab for COVID‐19 associated cytokine storm syndrome: Less is more},
  journal = {British Journal of Clinical Pharmacology},
  year = {2025},
  volume = {91},
  number = {4},
  pages = {938--946},
  doi = {10.1111/bcp.15690}
}
Kostenlos starten →